Purpose: Reliable biomarkers for predicting subsequent sepsis among patients with suspected acute infection are lacking. In patients presenting to emergency departments (EDs) with suspected acute infection, we aimed to evaluate the reliability and discriminant ability of 47 leukocyte biomarkers as predictors of sepsis (Sequential Organ Failure Assessment score ≥ 2 at 24 h and/or 72 h following ED presentation).
Introduction
Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection [1] . Host immune responses result from leukocytes sensing pathogen-and tissue damage-associated danger signals [2, 3] . Sepsisrelated immune responses involve both humoral and leukocyte components of the innate and adaptive immune systems, with excessive inflammation and immunosuppression occurring simultaneously in most patients [2, 3] . These are thought to influence the resulting clinical phenotypes and outcomes [3, 4] .
Leukocyte responses in sepsis measured using flow cytometry detect leukocyte biomarkers, including surface markers and/or leukocyte subsets [5] . Previous flow cytometry-based leukocyte biomarker studies in sepsis were mostly small, single-centre studies in patients with sepsis, typically focusing on a limited panel of biomarkers. These studies rarely evaluated biomarker reliability and reproducibility, which is methodologically and clinically relevant as it influences diagnostic validity [6] . In addition, few studies used robust unbiased designs to assess predictive ability for clinically relevant outcomes in unselected populations with suspected infections prior to developing organ dysfunction and established sepsis.
We hypothesized that among patients with clinically suspected acute infection, but without established sepsis, leukocyte biomarkers would identify patients who subsequently deteriorate clinically and develop sepsis, when measured within a few hours of presentation to the emergency department (ED). Our study objectives were: (1) to identify reliable leukocyte biomarkers; (2) to ascertain which of the reliable biomarkers could discriminate [6] acutely unwell patients with suspected infection from patients with community acquired sepsis-related critical illness in the intensive care unit (ICU) and/or ED patients with non-infective acute illness requiring hospitalisation; and (3) to ascertain whether any of the reliable biomarkers with cross-cohort discrimination could predict which patients with suspected infection in the ED subsequently develop sepsis. We also undertook a post hoc extreme phenotype analysis [7] , to compare the biomarker profiles between acutely unwell patients with suspected infection who subsequently developed most severe illness with those who recovered rapidly.
Methods

Study sites and ethics
We performed a prospective, multi-centre, observational cohort study at four sites in the United Kingdom. Ethical approval was granted by the Scotland A/ Oxford C Research Ethics Committees (13/SS/0023;13/ SC/0266). Consent was provided by patients or surrogate decision-makers according to capacity. We registered the study (NCT02188992) and published the protocol including the analysis plan [8] .
Cohort definitions and eligibility criteria
We recruited three distinct patient cohorts using an a priori sampling method to achieve similar age and sex profiles across the ED cohorts. Detailed inclusion/exclusion criteria are listed in the electronic supplement and published protocol (emethods-1) [8] . Cohort-1 comprised acutely unwell patients with suspected infection and systemic inflammation presenting to ED and formed the "discovery cohort". Patients considered by clinical teams to already have established severe sepsis and/or require ICU admission when screened were excluded. Cohort-2 comprised ICU patients with established community acquired sepsisrelated critical illness and formed the "true positive" cohort. Cohort-3 comprised acutely ill patients presenting to ED without infection or systemic inflammation, but requiring hospitalization and formed the "true negative" cohort. Inclusion criteria used throughout the study were based on the sepsis definitions by Levy et al. [9] , as our study was designed prior to the Sepsis-3 definitions [1, 10] . All ED patients were enrolled within 12 h of hospital presentation. For all cohorts, we excluded patients with acute pancreatitis, haematological malignancy, chemotherapy in the past 2 weeks, myelodysplastic syndromes, known neutropenia, HIV infection, viral hepatitis infection, pregnancy, blood transfusion > 4 units in the past week, oral corticosteroids for > 24 h prior to enrolment, or a decision not to have active therapy/for palliative care [8] .
Take-home message
In this first study of standardised multi-site flow cytometry in acutely unwell patients with suspected infections attending emergency departments, we explored which of 47 leukocyte biomarkers reliably discriminates which patients develop sepsis over the next 3 days, defined according to the Sepsis-3 sepsis criteria. After highlighting the importance of test reliability (14 biomarkers lacked measurement reliability) and comparator cohorts (a further 17 biomarkers did not discriminate acutely unwell patients with suspected infection from patients with established sepsis-related critical illness and/ or non-infective acute illness), we found that none of the remaining 16 biomarkers had clinically relevant predictive ability for subsequent sepsis or other important clinical outcomes. However, markers of early immune suppression (neutrophil and monocyte CD274 and CD279; monocyte HLA-DR) had the strongest associations with clinical outcomes. The optimum biomarker combination associated with clinical deterioration to sepsis was increased neutrophil CD24 and CD279 and reduced monocyte HLA-DR expression.
Leukocyte surface biomarkers and cross-site standardization of flow cytometry
We devised five separate flow cytometry panels to assess 47 leukocyte biomarkers with biological plausibility for having predictive validity for subsequent sepsis (eMethods-1; eTable-1; eFigure-1). We developed, standardized and harmonized flow cytometry procedures across all four study sites [8] . We performed flow cytometry within 4 h of sample acquisition. All antihuman antibodies conjugated to fluorochromes for flow cytometry were from the same batch and clones [all Becton-Dickinson Biosciences (BDB)], standardized on the same platform (FACSCanto II; BDB, San Jose, CA, USA), using a common batch of Cytometer Setup and Tracking beads with the same beads for daily internal quality controls, at all clinical sites. All flow cytometry standard (FCS) files were read by expert technicians using standardized gating procedures developed for each biomarker prior to analysis. The gating strategy for estimating median fluorescence intensity (MFI) or proportions is reported in eMethods-1. All FCS analysis technicians were blinded from clinical data.
Sample size
We based sample size estimates on the confidence interval (CI) widths for positive and negative predictive values (PPV and NPV). The initial design had a primary outcome of septic shock, with an estimated event rate of 5-10% in cohort-1 [11, 12] . For a range in test performance for PPV/NPV of 50-90% we planned a sample size of: cohort-1, n = 300; cohort-2, n = 100; and cohort-3, n = 100, to give a CI width between ± 4.6% to ± 9.8% for PPV and ± 3.4% to ± 6.3% for NPV. At an interim analysis of clinical event rates, the incidence of septic shock was substantially lower than anticipated. We decided by consensus to change the primary outcome to severe sepsis (and subsequently adopted the sepsis-3 sepsis criteria [1] of Sequential Organ Failure Assessment (SOFA) score ≥ 2), with critical care admission a key secondary outcome, to ensure adequate clinically relevant events in the discriminant analyses. These changes occurred prior to study completion and were reported in the published protocol [8] .
Statistical analysis
The primary study cohort was cohort-1. The primary exposure was suspected infection. The cohorts-2 and 3 were comparator populations for cross-cohort discrimination and biomarker selection.
Outcomes
The primary outcome was sepsis, defined as SOFA score ≥ 2 at 24 h and/or 72 h following presentation to hospital in patients with suspected infection in the ED (cohort-1) [1] . Secondary outcomes were: critical care admission or death within 72 h of presentation; SOFA ≥ 4 at 24 h and/or 72 h following presentation to hospital; development of septic shock; discharge home within 72 h; discharge to home or in hospital with no organ failure within 72 h; death from sepsis; confirmed infection and length of hospital stay [8] . All cohort-1 data are based on blood samples taken in the ED after recruitment.
Biomarkers selection strategy
Our analytic approach to discover biomarkers with potential diagnostic discrimination for risk of subsequent sepsis occurred in three a priori planned stages and one post hoc analysis.
Stage one: reliability
Inter-and intra-reader reliability for 47 different biomarkers was established according to the protocol [8] . To be included in subsequent evaluation stages, biomarkers needed to demonstrate both inter-and intra-reader reliability at the pre-defined intra-class correlation coefficient (ICC) between readers ≥ 0.9; see Fig. 1 and eMethods-2; eTable-2). For intra-reader reliability the ICC for each reader was calculated as the ratio of within-reader variability to the total variance (within-reader plus residual variance) from the normal linear mixed model. For inter-reader reliability the ICC was calculated as the ratio of between-reader variability to the total variance (between-reader plus residual variance) from the normal linear mixed model. Reliability analyses were done prior to linking leukocyte biomarkers data and clinical outcome data.
Stage two: cross-cohort discrimination
For reliable biomarkers, statistically significant intergroup differences between the three cohorts were explored using Kruskal-Wallis analysis of variance (ANOVA) tests (eTable-3) and visual inspection of data.
Biomarkers that discriminated between cohort-1 and either cohort-2 (true-positive) and/or cohort-3 (true negative) and had variability within cohort-1 consistent with potential to discriminate clinical outcomes were selected for Stage-3 analysis. Other factors considered were cell counts, the magnitude of MFI, and potential linkage and co-linearity between groups of biomarkers. This was done in consensus meetings by researchers blinded from clinical outcomes within cohort-1.
Stage three: prediction of clinical outcomes in cohort-1
Within cohort-1 patients, the ability of the selected biomarkers to predict the primary and secondary outcomes was calculated using univariate logistic regression. For the secondary outcomes of death from sepsis, septic shock and length of stay, we provided a descriptive summary as per the analysis plan [8] . The odds ratio (OR) for the outcome per standard deviation increase in biomarker, receiver operating characteristic (ROC) curves, and area under ROC curve (AUROC) were used to assess predictive ability. Youden's index identified the optimal cut-off point for each marker [13] . Candidate biomarkers that showed consistent inclusion were then taken forward for multivariable modelling. We used best subsets regression [14] to identify optimal combinations of predictive markers. Specifically, models containing a given number of biomarkers were fitted for all potential biomarker combinations. The five best-fitting models of a given size, according to the Chi squared score statistic, were identified. Biomarkers that consistently appeared in the best-fitting models were selected for the final model. The change in Chi squared score statistic between the best fitting models containing different numbers of biomarkers was used to determine the number of biomarkers to be included in the final model. Linearity of biomarker associations on the logistic scale was checked using plots of deviance residuals. Based on consistency and model fit we identified optimal combinations of predictive markers.
Post hoc extreme phenotype comparison
On the recommendation of a pre-planned independent expert group (see eTable-4), we compared biomarker profiles between sub-populations within cohort-1 with extreme clinical phenotypes of organ dysfunction and outcome to further explore associations for the biomarkers evaluated. We defined well and sick extreme phenotypes [7] by consensus among clinical investigators using clinical data without knowledge of group differences in biomarkers (eFigure-2). The well phenotype had no positive microbiology, a SOFA score ≤ 2 at 24 and 72 h post-enrolment and were either discharged home by 72 h or were in hospital but no longer receiving antibiotics. The sick phenotype had a confirmed infection, SOFA score ≥ 2 at both 24 and 72 h post-enrolment and were still in hospital and receiving antibiotics at 72 h. We compared biomarker expression between the two phenotypes using two-sample t-tests or Mann-Whitney tests as appropriate, applying Bonferroni correction for multiple testing.
For additional comparison, we also measured C-reactive protein (CRP) and procalcitonin (PCT) concentrations at the same time point for cohort-1 patients, given the widespread clinical use of these biomarkers in assessing infection. We constructed ROC curves for CRP and PCT and estimated similar univariate predictive performance characteristics of these for outcomes reported, to enable direct comparison of predictive validity with the more novel biomarkers.
Results
Patient characteristics
Between January 2014 and February 2016, we recruited 272, 59 and 75 patients (N = 406) to cohorts 1, 2, and 3, respectively. The clinical characteristics for the three cohorts and the cohort-1 outcomes are shown in Table 1 . Cohorts-1 and 3 had a similar age and sex distribution. Cohort-2 patients tended to be older. The primary outcome in cohort-1, clinical deterioration to sepsis, occurred in 139 patients (51.1%).
Stage one: reliability
The step-wise assessment of intra-reader and then interreader reliability resulted in rejection of 14 biomarkers as non-reliable, leaving 33 reliable biomarkers for crosscohort comparison ( Fig. 1 ; eTable-2).
Stage two: cross-cohort discrimination
Statistical comparison, expert review, and cohort-1 data distribution resulted in rejection of a further 17 biomarkers ( Fig. 1 ; eTable-2; eTable-3). The cross-cohort comparisons plots for the 16 selected biomarkers are shown in eFigure-3. Based on the stage-1 and -2 selections, eight neutrophil biomarkers [cluster of differentiation antigens (CD) CD15; CD24; CD35; CD64; CD312; CD11b; CD274; CD279], seven monocyte biomarkers (CD35; CD64; CD312; CD11b; HLA-DR; CD274; CD279) and one CD8 T-lymphocyte biomarker (CD279) were selected for evaluation of discrimination for clinical outcomes. Biological relevance of these markers in sepsis are summarized in Table 2 .
Stage three: prediction of clinical outcomes in cohort-1
Most biomarkers lacked any clinically or statistically significant discrimination for predicting primary and secondary outcomes within cohort-1 patients. Amongst the individual biomarkers, clinical deterioration to sepsis was associated with higher neutrophil CD279 expression, higher monocyte CD279 expression and lower monocyte HLA-DR expression. The optimal MFI cutoff for neutrophil CD279 was 239 [sensitivity 0.88 (95% confidence interval 0.82-0.93); specificity 0. . Although these associations were statistically significant, discriminant ability was poor and unlikely to be clinically useful in isolation.
With best subsets logistic regression, the optimum combination for predicting clinical deterioration to sepsis included increased neutrophil CD24; increased neutrophil CD279; and reduced monocyte HLA-DR expression [sensitivity 0.72(0.64-0.79); specificity 0.56(0.48-0.65)]. With best subsets logistic regression, the optimum combination for predicting the secondary outcome of discharge to home within 72 h, included increased neutrophil CD15, Reduced HLA-DR expression on monocytes is associated with increased risk of nosocomial infection due to impaired monocyte competence. Monocyte HLA-DR expression less than 8000 monoclonal antibodies/cell for 2 or more days can be reversed with GM-CSF therapy, with potentially beneficial effects [25] . This is a useful biomarker for enrichment in future clinical trials reduced neutrophil CD274 and increased total monocyte HLA-DR expression. No biomarkers had significant discriminant value for the outcome of critical care admission or death within 72 h. The performance of individual and optimized combinations of biomarkers for predicting the primary and secondary outcomes are shown in Table 3 . No marked non-linearities in biomarker effects were identified. Overall, although statistically significant associations were demonstrated, discrimination of clinical outcomes was unlikely to be clinically useful (Fig. 1) .
Extreme phenotype analysis
From 272 patients in cohort-1, we identified 40 "well' and 52 "sick" phenotypes (eFigure-2). "Sick" phenotype patients were characterized by being older, more often male, with a higher frequency of co-morbidities, more frequently lymphopenic, with higher APACHE II and SOFA scores at baseline. After Bonferroni correction for multiple comparisons, "sick" phenotypes had significantly higher monocyte CD279 and neutrophil CD279 in the ED, but no other biomarkers were different (Table 4 ; eFigure-4). For both CRP and PCT, there was also no statistically or clinically significant discrimination for subsequent sepsis with univariate analysis (Table 3) .
Discussion
In this multi-site cohort study, we reduced a candidate panel of 47 leukocyte biomarkers to 16 reliable biomarkers with potential for discriminating the risk of developing sepsis in patients with suspected infection presenting to the ED. The combination of higher neutrophil CD24, higher neutrophil CD279, and a lower monocyte HLA-DR expression best predicted the clinical deterioration to sepsis. Consistent with this association, a lower neutrophil CD279 expression and higher monocyte HLA-DR expression were associated with discharge home within 72 h (implying rapid recovery). Although our pre-defined biomarker discovery strategy identified these biomarkers as associated with development of sepsis and more severe illness, their discriminant value was insufficient to suggest utility for decision-making in routine clinical care.
Our findings have potential clinical relevance. The key pathophysiological insight is that leukocyte biomarkers of immunosuppression such as check-point inhibitors (CD279; CD274) and antigen processing ability (HLA-DR) were altered even in patients with suspected infection presenting to ED. We also demonstrate the importance of assessing reliability when standardising flow cytometry for large-scale time critical use. The development of clinically useable tests is likely to require a form of crossplatform calibration (such as multiparametric version of the Quantibrite system, BD Bioscience). Our study shows it is feasible to implement flow cytometry as a means of undertaking precision medicine in sepsis, for example to guide novel therapeutic interventions such as those tested recently in immunotherapy trials [15] and highlighted in recent expert reviews [16, 17] . However, our data suggest that for patients with suspected infection the predictive validity of panels of leukocyte biomarkers are unlikely to be useful as general clinical decision-making tools. Of note, both CRP and PCT also performed poorly.
Strengths of our study were well-defined hypothesis, pre-published protocol [8] , internationally accepted primary outcome [1] , clinically relevant secondary outcomes and hierarchical analytic approach to reduce biomarker selection bias. Reliability of multi-site flow cytometry is potentially problematic due to measurement error bias [18] , which we addressed rigorously with fluorochromeconjugated antibody titrated for optimal signal and kept constant throughout the study. Using hospitalized noninfected patients and ICU-sepsis patients as comparators during biomarker selection increased the chance of detecting infection related host responses and is superior to using healthy volunteer controls. Our blood sampling time point in the ED was prior to severe illness, before major clinical interventions, and much earlier than in previous studies of sepsis biomarkers, and we excluded patients who clinicians considered to have already established sepsis and/or critical illness. As such, our population was different from other recent studies, which evaluated leukocyte biomarkers for prediction of sepsis trajectory (by including patients with sepsis-2 defined sepsis, severe sepsis and septic shock) [19, 20] and stratified nosocomial infection risk in ICU patients [21] (see eTable-5, which highlights important differences). The post hoc extreme phenotype analysis enhanced face validity by considering multiple clinical variables simultaneously for phenotype definition.
Our study has potential weaknesses. Although we could not include all potential leukocyte biomarkers, we studied a range of leukocyte biomarkers (such as complement pathway receptors (CD35, CD11b), G protein-coupled receptors (CD312), Fc-gamma-receptors (CD64 [22, 23] ), factors delaying neutrophil apoptosis (CD24 [22] ), checkpoint molecules (CD274, CD279) [24] ; HLA-DR expression [25] [26] [27] ), that previous studies highlight association with adverse outcomes in established sepsis. We enrolled a smaller sample size than planned due to time and funding constraints. However, this had a limited impact since substantial differences in biomarker levels across cohorts still enabled selection of candidate biomarkers for further discriminant analysis. Supervised classification methods such as classification and regression trees (CART) is a valid alternative analytic approach for this research question. However, CART requires approximately 50 events 2SOFA score sequential organ failure assessment score; MFI median fluorescence intensity; CD Cluster of differentiation; ICU intensive care unit * Best subsets regression did not identify any combination models which provided better fit than individual marker models 1 As pre-specified, secondary outcomes of hospital mortality, occurrence of septic shock and length of stayare not reported Fig. 1 Overview of selection of leukocyte biomarkers for discriminant analysis through the pre-defined stages of the study. For a detailed description of the rationale for biomarker selection see eMethods-1 and eMethods-2. Non-reliable refers to the analysis of cell populations that are not sufficiently distinct in bimodal FACS plots, are difficult to reliably standardize for a uniform gating approach and need further development. We are proposing that these biomarkers are necessarily of limited value per variable when predicting a dichotomised outcome, before predictions become stable and over-optimism is minimised [28] . As our observed number of sepsis events did not reach this threshold we opted to use the best subsets logistic regression approach as pre-specified in our statistical analysis plan [8] . As our cohort-1 inclusion criteria mandated SIRS, we have excluded SIRS negative patients with infection, who could have progressed to develop sepsis. However, this is unlikely to bias the results, as the prevalence of SIRS negative sepsis-3 sepsis in ICUs in England is only 3% [29] . As our objective was to study leukocyte biomarkers at an earlier time point than previously achieved and to identify biomarkers that predict deterioration within 72 h of hospitalisation, we excluded patients planned for direct admission to ICU from the ED at enrolment, which explains the lower than expected event rate for death and septic shock. Findings might be different for more severely ill patients studied later in sepsis, as observed in other recent flowcyometric studies (eTable-5) [19] [20] [21] .
Our findings have biological plausibility, as the leukocyte biomarkers that best predicted the risk of developing sepsis in our study were on the key innate immune cells, namely neutrophils and monocytes, which are first responders to infection. The strongest biomarker predicting subsequent sepsis and extreme phenotypes was higher levels of CD279 (programmed death receptor 1, PD-1) on monocytes and neutrophils. CD279 expression is associated with neutrophil and monocyte suppressor subsets [30] , memory lymphocyte subsets [31] , is thought to regulate T cell responses and induce an inhibitory signal characterized by cell cycle arrest and reduced cytokine synthesis [2, 32] . This early role for CD279/PD-1 is consistent with animal models of sepsis [33] and sepsis cohorts [30] . CD279/PD-1 acts in conjunction with its ligand CD274 (PD-L1). In our study, lower CD274, together with lower CD279, higher monocyte HLA-DR, and lower neutrophil CD24, emerged as a predictor for rapid recovery sepsis phenotype. These novel findings require further confirmatory studies.
Although none of the biomarkers we studied had discriminant ability that could be used to guide clinical decision-making, our data imply that immunosuppression in infected patients precedes established sepsis and that higher CD279/PD-1 and lower HLA-DR are potential theragnostic and enrichment markers [34] [35] [36] [37] for anti-PD-1/PDL-1 agents and granulocyte-monocyte colony stimulating factor [25] , respectively, for carefully designed immunotherapy trials [3, 38] .
Conclusions
We conclude that in a population of patients presenting with suspected infection prior to established sepsis, a sequential approach to identifying reliable potential leukocyte biomarkers from a large candidate panel that may predict the subsequent development of sepsis identified only a small number with discriminant properties. These were markers of immune suppression, namely CD279 and HLA-DR, suggesting this may be an early event, prior to development of sepsis.
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